10X GENOMICS Closes at $47.52, Down -0.44% from Previous Session.
March 6, 2023
Trending News 🌥️
10X GENOMICS ($NASDAQ:TXG), Inc. is a genomic analysis company that specializes in single-cell genomics. Recently, an analysis of the technical features of 10X Genomics Inc. was conducted, revealing that the company’s stock closed at $47.52 in the most recent trading session, representing a 0.44% decrease from the previous closing price of $47.73. This marks a slight drop in the value of 10X Genomics, Inc.’s stock, indicating an overall bearish sentiment towards the company’s performance. The company offers a wide range of products and services related to genomic analysis, including single-cell sequencing, gene expression profiling, and other technology solutions. Despite the slight downturn in its stock price, 10X Genomics Inc. remains one of the most prominent players in the genomic analysis market.
Moreover, the company is continuing to roll out new advancements in its offerings and technology solutions, further cementing its position as a leader in genomic analysis. Overall, 10X Genomics Inc. closed at $47.52 in the most recent trading session, which was down 0.44% from the previous session’s closing price of $47.73. Investors may want to closely monitor the latest news and developments related to 10X Genomics, Inc., as well as any changes in the company’s stock price.
Share Price
Despite the slight drop, the stock opened at $45.6, up 3.5% from last closing price of $46.6. Trading volume was high, with over 5 million shares traded on the day. The stock has been under pressure given the current market conditions and uncertainty in the industry. Despite the bumpy ride, it will be interesting to see how 10X GENOMICS stock reacts in the coming days. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 10x Genomics. More…
| Total Revenues | Net Income | Net Margin |
| 516.41 | -166 | -32.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 10x Genomics. More…
| Operations | Investing | Financing |
| -33.61 | -350.89 | 15.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 10x Genomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.03k | 223.24 | 6.99 |
Key Ratios Snapshot
Some of the financial key ratios for 10x Genomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 28.1% | – | -31.3% |
| FCF Margin | ROE | ROA |
| -32.0% | -12.8% | -9.8% |
Analysis
At GoodWhale, we offer in-depth analysis of 10X GENOMICS‘ financial fundamentals. Our Risk Rating analysis gives 10X GENOMICS a high risk investment rating, taking into account both business and financial risks. GoodWhale’s analyses have detected five risk warnings, which are visible in the income sheet, balance sheet, cashflow statement, and non-financial and financial journals. All associated risk warnings are provided to registered users of our platform. Our platform can help you make smarter, more informed decisions when considering investments in 10X GENOMICS. More…
Peers
The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.
– Certara Inc ($NASDAQ:CERT)
Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.
– Omnicell Inc ($NASDAQ:OMCL)
Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.
Summary
Investing in 10X Genomics can be a great strategy for long-term returns. The stock recently closed at $47.52, down a mere 0.44% from the previous session.
However, the stock price moved up the same day, showing potential for potential investors. 10X Genomics is an emerging and innovative biotechnology company that focuses on advancing genomic technologies. Its solutions are helping unlock important scientific discoveries and enabling better diagnosis and treatment of disease. The company’s products are being used to gain insights into many diverse areas, such as cancer research and personalized medicine. Potential investors should take into account the long-term potential of the company, as well as recent performance. Analysts project that 10X Genomics is well-positioned for strong growth over the coming years, which could lead to attractive returns for investors.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
